Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy

Outcomes for infants diagnosed under 1 year of age with KMT2A-rearranged acute lymphoblastic leukemia (ALL) have remained stagnant over the past 20 years. Successive treatment protocols have previously focused on intensification of conventional chemotherapy, but increased treatment-related toxicity and chemoresistance have led to a plateau in survival.

Citation:
Kotecha RS. Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy. Hematology Am Soc Hematol Educ Program. 2022;2022(1):611-7.

Keywords:
Antineoplastic Agents; therapeutic use; immunotherapy; infant; molecular targeted therapy; precursor cell lymphoblastic leukemia-Lymphoma; drug therapy

Abstract:
Outcomes for infants diagnosed under 1 year of age with KMT2A-rearranged acute lymphoblastic leukemia (ALL) have remained stagnant over the past 20 years. Successive treatment protocols have previously focused on intensification of conventional chemotherapy, but increased treatment-related toxicity and chemoresistance have led to a plateau in survival.